ASHP-Midyear-Spotlights-New-COPD-Treatments

By Marcus A. BanksAfter several decades without new treatment options for chronic obstructive pulmonary disease (COPD), three new drugs gained FDA approval over the past two years: the biologics dupilumab (Dupixent, Sanofi and Regeneron) and mepolizumab (Nucala, GlaxoSmithKline) and inhaled ensifentrine (Ohtuvayre, Verona).Crystal light - stock.adobe.com“This is exciting. We’ve mostly been using the same medications to treat COPD for the last 20 or 30 years,” said Nathan Pinner